Compare Bristol-Myers Squibb Co (BMY) vs GE Aerospace (GE) Price & Performance

Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.

BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.

GE trades at $353.73, down 1.54% today, with a bullish technical signal from moving averages and oversold RSI levels. The company reported strong Q1 2026 earnings of $1.86 per share, beating estimates, supported by robust aerospace demand and defense contract wins. Revenue grew to $45.86 billion in 2025, with net income margins improving to 17.86%. Analysts maintain a bullish consensus with a $397 price target, citing order growth and backlog strength.

Outlook remains positive due to aerospace momentum and strategic investments, but high valuation ratios (P/E 43.9) and debt levels pose risks. The stock offers upside to consensus targets, though investors should monitor execution on growth initiatives and macroeconomic pressures on defense spending.